Last reviewed · How we verify
DAO supplement
DAO (diamine oxidase) supplement provides exogenous enzyme to break down histamine in the gastrointestinal tract, reducing histamine accumulation.
DAO (diamine oxidase) supplement provides exogenous enzyme to break down histamine in the gastrointestinal tract, reducing histamine accumulation. Used for Histamine intolerance, Gastrointestinal symptoms associated with elevated histamine.
At a glance
| Generic name | DAO supplement |
|---|---|
| Also known as | PEA SPROUT DEHYDRATED POWDER |
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Drug class | Enzyme supplement |
| Target | Histamine (substrate); diamine oxidase enzyme |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Allergy / Histamine Intolerance |
| Phase | FDA-approved |
Mechanism of action
DAO is a naturally occurring enzyme that catalyzes the degradation of histamine in the small intestine. By supplementing with exogenous DAO, the product aims to reduce histamine levels in patients with histamine intolerance or elevated endogenous histamine. This may alleviate symptoms associated with histamine accumulation, such as gastrointestinal distress, headaches, and allergic-like reactions.
Approved indications
- Histamine intolerance
- Gastrointestinal symptoms associated with elevated histamine
Common side effects
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. (PHASE4)
- Evaluation Of The Diamine Oxidase Supplementation Effect In Patients With Insomnia Symptoms (NA)
- Fatty Acids in Airway Smooth Muscle of Asthmatics (NA)
- Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS (PHASE4)
- Nutritional Supplement for Patients With Severe Infection (NA)
- The Effect of Food Supplements on Food Intake and Gut Hormone Levels (NA)
- Study to Investigate the Effect of an Oral Diamine Oxidase Substitution (DAOsin) in Histamine Intolerant Patients on the Low Endogenous Diamine Oxidase Serum Activity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAO supplement CI brief — competitive landscape report
- DAO supplement updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI